Concepedia

Publication | Closed Access

Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study

DOI

26

Citations

0

References

2022

Year

Mary E. Westerman, Kelly K. Bree, Pavlos Msaouel, Janet Baack Kukreja, Cheryl Mantaring, Innocent Rukundo, Martha Garcia Gonzalez, Justin R. Gregg, Kelly N. Casteel, Surena F. Matin
The Journal of Urology

Abstract

There were fewer compliance events using apixaban for EP than enoxaparin after urologic oncology surgery. Regarding safety, apixaban is noninferior to enoxaparin and may in fact have fewer associated major complications.